Mark‐David Levin

Bortezomib, thalidomide, and dexamethasone with or without daratumumab before and after autologous stem-cell transplantation for newly diagnosed multiple myeloma (CASSIOPEIA): a randomised, open-label, phase 3 study

Philippe Moreau, Michel Attal, Cyrille Hulin et al. · The Lancet · 2019 · 922 citations · Full text

Hematological Malignancy, Radiation Oncology, Medicine +9

Autologous haematopoietic stem-cell transplantation versus bortezomib–melphalan–prednisone, with or without bortezomib–lenalidomide–dexamethasone consolidation therapy, and lenalidomide maintenance for newly diagnosed multiple myeloma (EMN02/HO95): a multicentre, randomised, open-label, phase 3 study

Michèle Cavo, Francesca Gay, Meral Beksaç et al. · The Lancet Haematology · 2020 · 377 citations · Full text

Hematological Malignancy, Transplantation, Marrow Transplantation +9

COVID-19 severity and mortality in patients with chronic lymphocytic leukemia: a joint study by ERIC, the European Research Initiative on CLL, and CLL Campus

Lydia Scarfò, Thomas Chatzikonstantinou, Gian Matteo Rigolin et al. · Leukemia · 2020 · 271 citations · Full text

First-Line Venetoclax Combinations in Chronic Lymphocytic Leukemia

Barbara Eichhorst, Carsten Utoft Niemann, Arnon P. Kater et al. · New England Journal of Medicine · 2023 · 268 citations · Full text

Oral ixazomib maintenance following autologous stem cell transplantation (TOURMALINE-MM3): a double-blind, randomised, placebo-controlled phase 3 trial

Meletios Α. Dimopoulos, Francesca Gay, Fredrik Schjesvold et al. · The Lancet · 2018 · 231 citations · Full text

Regenerative Medicine, Cell Therapy, Transplantation +7